Special Issue "Advances in Drug Design"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 July 2012)

Special Issue Editor

Guest Editor
Dr. Arthur Gomtsyan
Abbvie Inc, Drug Discovery, 1 North Waukegan Road, Department ZR09, Bldg. AP10, North Chicago, IL 60064, USA
E-Mail: arthur.r.gomtsyan@abbott.com
Phone: +1 847 935 4214
Fax: +1 847 937 9195
Interests: medicinal chemistry; synthetic organic chemistry; drug design in the area of pain and dermatology research

Special Issue Information

Dear Colleagues,

Productivity of the pharmaceutical industry measured in terms of a number of approved drugs has been in decline over the last several decades. New creative approaches in drug design have been put in place to reverse that trend. Structure-based drug design that relies on high resolution 3D structures of drug targets is being complimented with fragment-based drug design approach which utilizes NMR spectroscopy to shorten the time of lead generation. On the other hand, closer attention is drawn to a drug-likeness of molecules – molecular weight, solubility, lipophilicity, etc. Lipinski's rule of five or its modifications are gaining prominence in medicinal chemistry decision making. Cheminformatic tools are becoming part of arsenal for medicinal chemists. Drug design takes into account not only pharmacological properties, but also potential toxicological effects of the molecules. Potential for reactive metabolite formation and protein covalent binding now can be assessed with various successes in vitro to predict idiosyncratic toxicity in clinic. New procedures including in silico models can be implemented to predict pharmacokinetic properties of the compounds.
Prevailing dogma in drug discovery that values selective compounds the most is getting challenged with a concept of polypharmacology, which suggests that multitargeted drugs, compared with selective drugs, may display better efficacy in clinic. As far as the mechanism of drug action goes, concept of allosteric modulation is more widely employed in a number of therapeutic areas.

Dr. Arthur Gomtsyan
Guest Editor

Keywords

  • structure-based drug design
  • fragment-based drug design
  • drug-likeness, rule of five
  • cheminformatics
  • predictive methodologies for ADME and drug toxicity
  • polypharmacology
  • allosteric modulators

Published Papers (6 papers)

Download All Papers
Sort by:
Display options:
Select articles Export citation of selected articles as:
Select/unselect all
Displaying article 1-6
p. 1128-1146
by , , , ,  and
Pharmaceuticals 2012, 5(10), 1128-1146; doi:10.3390/ph5101128
Received: 31 July 2012; in revised form: 24 September 2012 / Accepted: 15 October 2012 / Published: 23 October 2012
Show/Hide Abstract | PDF Full-text (337 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Advances in Drug Design)
p. 1450-1474
by , , ,  and
Pharmaceuticals 2011, 4(11), 1450-1474; doi:10.3390/ph4111450
Received: 8 August 2011; in revised form: 20 October 2011 / Accepted: 20 October 2011 / Published: 27 October 2011
Show/Hide Abstract | Cited by 5 | PDF Full-text (787 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Advances in Drug Design)
abstract graphic
p. 1328-1354
by , , , , , , ,  and
Pharmaceuticals 2011, 4(10), 1328-1354; doi:10.3390/ph4101328
Received: 21 September 2011; in revised form: 27 September 2011 / Accepted: 30 September 2011 / Published: 13 October 2011
Show/Hide Abstract | Cited by 1 | PDF Full-text (1239 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Advances in Drug Design)
p. 1236-1247
by , , , , , ,  and
Pharmaceuticals 2011, 4(9), 1236-1247; doi:10.3390/ph4091236
Received: 26 August 2011; in revised form: 13 September 2011 / Accepted: 16 September 2011 / Published: 20 September 2011
Show/Hide Abstract | Cited by 4 | PDF Full-text (549 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Advances in Drug Design)
abstract graphic
p. 1196-1215
by , , , , , , ,  and
Pharmaceuticals 2011, 4(9), 1196-1215; doi:10.3390/ph4091196
Received: 5 August 2011; in revised form: 23 August 2011 / Accepted: 29 August 2011 / Published: 1 September 2011
Show/Hide Abstract | Cited by 8 | PDF Full-text (2144 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Advances in Drug Design)
p. 758-769
by
Pharmaceuticals 2011, 4(5), 758-769; doi:10.3390/ph4050758
Received: 28 March 2011; in revised form: 17 May 2011 / Accepted: 20 May 2011 / Published: 20 May 2011
Show/Hide Abstract | PDF Full-text (238 KB) | HTML Full-text | XML Full-text | Supplementary Files
(This article belongs to the Special Issue Advances in Drug Design)
Select/unselect all
Displaying article 1-6
Select articles Export citation of selected articles as:

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.


Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert